The objectives of this proposal are to characterize the consequences of the interaction of the Abeta peptide with human microglia. In the brains of individuals affected by AD, microglia are clustered around the Abeta plaques. A range of experimental data have shown that microglia become activated to a pro-inflammatory state as a result of an interaction with Abeta. These activated microglia are producing a range of toxic products that can be causing damage to the neurons. There are still many mechanisms involved in the interaction of microglia with Abeta that remain to be worked out. We have developed a unique model, employing microglia cells that are derived from postmortem human brains, to study these mechanisms. The first specific aim of this application will compare the activation properties of different types of Abeta peptides on microglia in terms of their induction of macrophage colony stimulating factor, monocyte chemotactic protein, neurotoxic factor, superoxide radicals and expression of the enzyme myeloperoxidase. We will also examine whether antibody coated Abeta peptides have the same effect on microglial activation, and determine the relative roles of potential Abeta receptors in mediating this activation.
In specific aim 2, we will characterize the expression of the urokinase plasminogen activator receptor (uPAR) by microglia. This receptor plays a central role in coordinating the migration and adhesion of inflammatory cells and treatment of microglia with Abeta increases the expression of uPAR. In conjunction with this, we will determine whether the ligand urokinase plasminogen activator is induced and regulated in the same manner as the receptor. The consequences of binding to microglial uPAR will be investigated to characterize which signaling pathways are activated.
In specific aim 3, we will use immunochemical and biochemical techniques to study what is happening to the Abeta peptide once it has interacted with microglia. Microglia appear to have only limited abilities to degrade the Abeta peptides over time once phagocytosed. We propose to study whether the peptide is degraded, is complexed or undergoes other modifications. With the availability of gene array and isolation techniques and human genetic data, in specific aim 4 we propose to discover new consequences of Abeta-microglial interactions. Overall, the findings from the proposed research could extend our knowledge of the inflammatory events occurring in the AD brain.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG018345-02
Application #
6533878
Study Section
Special Emphasis Panel (ZRG1-BDCN-4 (01))
Program Officer
Snyder, Stephen D
Project Start
2001-09-01
Project End
2004-08-31
Budget Start
2002-09-01
Budget End
2003-08-31
Support Year
2
Fiscal Year
2002
Total Cost
$251,400
Indirect Cost
Name
Sun Health Research Institute
Department
Type
DUNS #
City
Sun City
State
AZ
Country
United States
Zip Code
85351
Walker, Douglas G; Dalsing-Hernandez, Jessica E; Lue, Lih-Fen (2008) Human postmortem brain-derived cerebrovascular smooth muscle cells express all genes of the classical complement pathway: a potential mechanism for vascular damage in cerebral amyloid angiopathy and Alzheimer's disease. Microvasc Res 75:411-9
McLarnon, James G; Ryu, Jae K; Walker, Douglas G et al. (2006) Upregulated expression of purinergic P2X(7) receptor in Alzheimer disease and amyloid-beta peptide-treated microglia and in peptide-injected rat hippocampus. J Neuropathol Exp Neurol 65:1090-7
Walker, Douglas G; Link, John; Lue, Lih-Fen et al. (2006) Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. J Leukoc Biol 79:596-610
McLarnon, James G; Choi, Hyun B; Lue, Lih-Fen et al. (2005) Perturbations in calcium-mediated signal transduction in microglia from Alzheimer's disease patients. J Neurosci Res 81:426-35
Walker, D G; Lue, L-F (2005) Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases. J Neurosci Res 81:412-25
Arancio, Ottavio; Zhang, Hui Ping; Chen, Xi et al. (2004) RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 23:4096-105
Roher, Alex E; Kuo, Yu-Min; Esh, Chera et al. (2003) Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease. Mol Med 9:112-22
Lue, Lih-Fen; Walker, Douglas G (2002) Modeling Alzheimer's disease immune therapy mechanisms: interactions of human postmortem microglia with antibody-opsonized amyloid beta peptide. J Neurosci Res 70:599-610
Roher, Alex E; Weiss, Nicole; Kokjohn, Tyler A et al. (2002) Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 41:11080-90
Walker, Douglas G; Lue, Lih-Fen; Beach, Thomas G (2002) Increased expression of the urokinase plasminogen-activator receptor in amyloid beta peptide-treated human brain microglia and in AD brains. Brain Res 926:69-79

Showing the most recent 10 out of 11 publications